The present study: describes the extent of simultaneous control of hemoglobin Alc (HbAlc), LDL-C, and BP, measures the association among intermediate outcomes, and identifies patient characteristics associated with simultaneous control of these outcomes among primary care patients with diabetes.
METHODS
For eligible patients who received care from the Veterans Affairs (VA) health care system in Fiscal Year (FY) 1999, we extracted data on HbAlc, LDL-C, and BP (systolic [SBP] and diastolic [DBP] ) for FY2000 (October 1, 1999 to September 30, 2000) . The study was approved by the Institutional Review Board of the Durham, NC, VA Medical Center.
Data Sources
Veterans Health Administration (VHA) Diabetes Registry and Dataset. The VHA Diabetes Registry and Dataset was used to obtain outcomes data and establish the diabetes cohort. The Registry contains 3 flies. The Pharmacy File has medication data for patients who have filled an outpatient prescription for insulin, oral hypoglycemic agents, or blood glucose monitoring supplies at any VA. The Laboratory File contains data on tests directly related to diabetes (including HbAlc and LDL-C]. The Vitals File has information on patient height, weight, body mass index (BMI), BP, and receipt of influenza and pneumonia vaccines, is Information is transmitted to the Registry via yearly downloads of diabetes-related data from individual VA-facility computer systems. Pharmacy file data are included on patients with a filled outpatient prescription for insulin, oral hypoglycemic agents, or glucose monitoring supplies. Laboratory and vitals data are included for patients who have _> 1 VA inpatient admission and/or > 2 VA outpatient encounters with Manuscript received November 9, 2005 Initial editorial decision January 27, 2006 Final acceptance April 5, 2006 an associated International Classification of Disease 9-Clinical Modifications (ICD-9-CM) diagnosis code for diabetes. 26 Specific variables captured by the Registry include: HbAlc, LDL-C, BP, BMI, and pharmaceutical treatment. 
VHA

Subjects--Diabetes Cohort
We used the VHA Diabetes Registry, Medical SAS Datasets, and BIRLS to construct a national cohort of diabetes patients who received VA primary care services. Patients identified as having diabetes had to meet both pharmacy and utilization criteria.
During FY1999, 503,371 patients were in the VHA Diabetes Registry. 26 We identified 224,221 patients who met all the following inclusion criteria during FY1999: (1) were alive on October 1, 1999 (using BIRI~ and Medical SAS Datasets); (2) _> 2 nonmental health outpatient visits with an associated diabetes diagnosis, and/or > 1 nonmental health inpatient discharge with an associated diagnosis of diabetes (using Medical SAS Datasets); (3) filled > 1 prescription for insulin, oral hypoglycemic agents, or blood glucose monitoring supplies (using Diabetes Registry); and (4) had _> 1 outpatient visit to a VA primary care clinic (using Medical SAS Datasets).
Individuals were considered primary care patients of the VA facility where they made the greatest number of primary care visits during 1999. In case of a tie, the patient was randomly assigned to 1 of the tied locations. Once patients' primary care clinics were determined, a random sample of 800 diabetes patients meeting the above criteria was drawn from each VA facility operating in 1999. 31 Ifa location did not have 800 eligible patients, all eligible patients were retained.
Subjects--Study Exclusion Criteria
Patients were excluded from this study ff they met any of the following criteria: (1) did not have a record for each intermediate outcome in 2000 and a BMI measurement (excluded so that all analyses include the same patients); (2) age < 18 years; (3) had a VA endocrinology visit during 1999 to 2000 {because determinants of control may be different for patients enrolled in specialty clinics32); (4) 
Data Analysis
Except where stated otherwise, statistical analyses were conducted using SAS ~ version 9.1. 35 We calculated the percentages of cohort members who achieved simultaneous diabetes control in 2000 using both of the above definitions.
To estimate the associations between having control of 1 intermediate outcome when having control of another, we calculated the percent of patients with control of other intermediate outcomes (e.g., LDL-C, BP) when a given outcome (e.g., HbAlc) is and is not in control. This was done to represent what might be seen among members of a clinic patient population. Unadjusted associations were also examined by calculating unadjusted odds ratios (OR) behveen control of different outcomes and Pearson correlations between intermediate outcomes (results available from authors).
It is possible that there is an overestimate of simultaneous control because patients without a record for a given outcome may be less likely to have control. As a result, a sensitivity analysis was conducted among all otherwise eligible patients with at least 1 intermediate outcome recorded. In this analysis, patients without all 3 intermediate outcomes were counted as not having simultaneous control.
Separate logistic-regression models were fit using both VA and ADA guidelines. The dependent variables were dichotomized (achieving control or not). For each model, ORs and Wald confidence limits were calculated for the simultaneously adjusted relationship between control and (1) To determine the difference in expected levels of other outcomes when 1 outcome is under control, separate simple linear-regression models were fit for each definition of individual control. The dependent variable was the continuous value for the outcome. Independent variables included control of the other 2 outcomes. For example, the model for HbAlc using the 1997 VHA guideline definition included LDL-C < 130mg/dL and BP < 140/90mmHg as independent variables. Other independent variables were identical to those in logistic-regression models.
Because patients are treated by individual primary care programs (clusters), we performed all logistic and linear regression models with the Huber-White estimate of variance 36 (g 37 (using Intercooled Stata ¢~ version 8.2 ).
RESULTS
Analyses included 80,207 patients who met the inclusion/exclusion criteria. These individuals were primary care patients at 541 VA locations in 1999. Table 1 describes characteristics of the patients.
The following percentages of the 144,176 otherwise eligible patients with at least 1 intermediate outcome reported did not have records for the individual outcomes: HbAlc (19.3%), LDL-C (38.5%), and BP (3.5%). Of 89,428 patients otherwise eligible, 9.80/0 were excluded from the final analyses based on requiring a record of a BMI.
Based on the VHA practice guidelines, 30.7% achieved simultaneous control (Table 2) . Percentages for control of individual outcomes were: HbAlc (81.5%), LDL-C (77.2%), and BP (47.5%). Using the more stringent ADA guidelines, only 3.9% of patients achieved simultaneous control, and fewer patients achieved control for each individual outcome: HbAlc (36.2%), LDL-C (40.7%), and BP (22.7%). Sensitivity analyses counting patients without all 3 intermediate outcomes recorded as not having simultaneous control led to estimated rates of simultaneous control of 17.3% of patients based on 1997 VHA guidelines and 2.2% of patients based on 2004 ADA guidelines.
Patients with control of any 1 parameter of diabetes care (i.e., HbA1c, LDL-C, BP) were only slightly more likely to have control of other parameters. For example, 48% of patients with LDL-C < 130mg/dL had good BP control, compared with 44% of patients with LDL-C _> 130mg/dL. The unadjusted association between control of blood sugar and LDL-C was stronger but still not tightly correlated; adequate glycemic control was present in 83% of patients with LDL-C < 130mg/dL, compared with 75% of patients with LDL-C _> 130mg/dL. There was a very small unadjusted inverse relationship between LDL-C control was even smaller (OR----1.26; 95% CI 1.21, 1.30), and there was essentially no association between BP and HbAlc control (OR=0.95; 95% CI 0.92, 0.99). While fewer patients achieved control of these outcomes using the more stringent ADA definitions, the magnitudes of the associations were similar (results available upon request from authors).
In order to provide a context for the associations between control of individual outcomes, we performed linear regression analysis with each clinical risk factor as a continuous variable outcome (adjusting for all factors used in the logistic models}. For example, Table 5 displays the expected differences in LDL-C, SBP, and DBP when I has control of HbAlc. Results show only small-adjusted differences in each outcome between patients in and out of control of each of the other clinical parameters. For example, the difference between LDL-C for patients with good control of HbA1c and those with poor control was 6.67mg/dL, favoring those with good HbAlc control. Other differences were of even smaller magnitude.
DISCUSSION
In a health care system that has been shown to deliver superior quality care and provide access to comprehensive primary care services, 13'38 simultaneous control of diabetes outcomes by the standards of the era was achieved only by approximately one-third of veterans. Furthermore, the associations between control of individual risk factors are, for the most part, clinically unimportant. 3'5 Only the relationship between control of HbAlc and LDL-C has slight clinical relevance.
Numerous medical, behavioral, and organizational interventions have been developed in recent years aimed at controlling major cardiovascular risk factors among diabetic patients. 2a24 This is often done under the assumption that there are underlying mechanisms that lead to overall lowering of risk if there is focus on a limited set of these outcomes (e.g., HbAlc). For example, many believe patient characteristics (e.g., nonadherence) may lead to inadequate control of chronic illnesses. 39 This perspective implies that interventions addressing these characteristics (e.g., pill boxes) can simultaneously improve multiple clinical outcomes. However, our results indicate that there is little relationship between control of the principal intermediate outcomes in diabetes. The present data suggest that success with 1 outcome may not portend the same benefits in other outcomes, even for the same disease.
Clinicians and researchers need to consider the potential implications of this research. Clinicians may not wish to aggressively pursue only 1 intermediate outcome under the assumption that others will then be controlled. Also, interventions may be faulty if they are based on an assumption that, for example, a patient is simply "nonadherent" or "passive." Rather researchers should explore adherence to or interest in specific behaviors and treatments relating to particular management problems. 4°
Results from logistic-regression models for control of individual intermediate outcomes show a significant relationship between BMI and all outcomes. Among variables included in the analyses, the largest association with simultaneous control reflects the well-documented relationship between This study has limitations and considerations. First, we lack data on important confounders, especially lifestyle behaviors associated with our outcomes {e.g., physical activity, diet, smoking status}. 41'51 Second, the study was conducted among VA users, virtually all of whom are male and many have complex chronic conditions. Finally, it is possible that our estimate of the rate of simultaneous control is high. Our calculation taking this possibility into account lead to estimates of simultaneous control as low as 17.3% for the definition based on the 1997 VHA guidelines and 2.2% for the more stringent 2004 ADA guidelines.
In summary, there is increasing recognition that control of vascular risk factors for patients with diabetes is critical to reduce morbidity and mortalityJ ~ Our results suggest that health care providers cannot assume that successfully achieving therapeutic goals for 1 risk factor will be associated with simultaneous control of other risk factors. Indeed, improving the quality and outcomes of diabetes care may require the consideration of individual characteristics when developing innovative strategies. These findings do not negate the importance of interventions that direct resources toward self-management support, organizational structures and processes, or broad behavioral adaptations. 52 Rather, our Findings suggest the importance of addressing and monitoring individual outcomes when attempting to achieve therapeutic goals for multiple outcomes simultaneously. This may include both specific medical management and addressing psychosocial issues faced by patients (e.g., readiness to change behaviors aimed at specific intermediate outcomes and social support for those changes). 53 We 
